Stay updated with breaking news from Graphite Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Graphite Bio voluntarily paused a Phase 1/2 test of its gene-edited therapy for sickle cell disease after the first patient in the study developed a serious blood complication. The setback will also delay plans to reach the clinic with another genetic medicine in its pipeline.
Gene therapy firm Graphite Bio said on Thursday it was pausing an early-to-mid-stage trial of its blood disease therapy due to a serious adverse event in the first patient dosed, sending its shares down nearly 48% in after hours trading.
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday. The Dow traded up 1.69% to 33,488.01...
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday. The Dow traded up 2.14% to 33,634.19...
(Reuters) - Gene therapy firm Graphite Bio said on Thursday it was pausing an early-to-mid-stage trial of its blood disease therapy due to a serious a...